anti-inflammatory agent

Isoxepac (Olopatadine USP Related Compound C) is a non-steroidal anti-antiphlogistic agent and analgesic.

Anti-inflammatory agent 49 is a potent inhibitor of Drp1-Fis1 interaction, inhibits GTPase, and can be used in the study of diseases caused by mitochondrial dysfunction.

Anti-inflammatory agent 42 has anti-inflammatory activity and inhibits the expression of TNF-α and IL-6 in LPS-stimulated macrophages.

Anti-inflammatory agent 51 is an amide sulfonamide derivative with anti-inflammatory and potentially anti-tumor activity and inhibition of NF-κB activation, which can be used to study acute lung injury and ulcerative colitis.

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Anti-inflammatory agent 1 is a chemical compound designated for reducing inflammation, structurally characterized by a [carboxyl acid], [oxygen], and [hydrocarbon] ring, with notable efficacy in mitigating inflammatory responses.

Compound 2g (Anti-inflammatory agent 93) is an active compound that exhibits analgesic activity.

Anti-inflammatory agent 94 (compound 4b) is an effective cannabinoid ligand with Ki values of 29 nM for CB2 and 8 nM for CB1. It is applicable in inflammation research.

Anti-inflammatory agent 95 (Compound 2e) is a compound with potent anti-inflammatory properties, showing significant inhibition of NO production in LPS-induced RAW 264.7 mouse macrophages, with an IC50 of 8.8 μM. It also effectively suppresses the secretion of TNF-α and IL-1β, achieving inhibition rates of 60% and greater than 90% at 100 μM, respectively. Anti-inflammatory agent 95 holds promise for research into inflammatory diseases.

Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial agent used in tuberculosis (TB) research, inhibiting the growth of Mtb H37Rv and M299 with MIC50 values of 2.3 and 7.8 μM, respectively. This compound also suppresses the expression of iNOS, thereby inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial agent used in tuberculosis (TB) research. It inhibits the growth of Mtb H37Rv and M299 with MIC 50 values of 1.3 and 6.9 μM, respectively. Additionally, it reduces inflammation by suppressing iNOS expression and inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 14 (compound 28) exhibits a MIC50 of 2 μM for Mtb H37Rv and also functions as an anti-inflammatory agent [1].

Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1].

Anti-inflammatory agent 9 (compound 28) is a benzimidazothiazole derivative derived from tilomisole, exhibiting higher COX-2 enzyme affinity than COX-1, thereby demonstrating promising anti-inflammatory properties and oral bioavailability [1].

Anti-inflammatory agent 22 (compound 14a) is a potent orally active compound with anti-inflammatory properties, effectively inhibiting LPS-induced TNF-α production with an IC50 of 14.6 μM. Additionally, Anti-inflammatory agent 22 prevents adipogenesis and effectively suppresses limb lymphedema volume in mice, holding promise for treating inflammation-related conditions, particularly lymphedematous tissue disorders [1].

Anti-inflammatory agent 8 (compound 13), designated as an anti-inflammatory agent 8, displays enhanced activity on the COX-2 enzyme compared to COX-1, with an IC50 value of 0.09 nM, and exhibits oral bioavailability [1].

Anti-inflammatory agent 16 (compound 14) is a potent peptidomimetic that significantly reduces the expression levels of TNFα, NO, CD40, and CD86 [1].

Anti-inflammatory agent 21 (compound 9o) is a low cytotoxic, orally active anti-inflammatory agent that targets NO (IC50: 0.76 μM). It accumulates ROS and inhibits the NF-κB MAPK signaling pathway to exert anti-inflammatory effects, showing beneficial effects on cartilage destruction and inflammatory cell infiltration in a rat model of arthritis.

Anti-inflammatory agent 10 is a tilomisole-based benzimidazole-thiazole derivative that is orally active. anti-inflammatory agent 10 is more active against COX-2 enzymes than COX-1.

Anti-inflammatory agent 13 is a pentacyclic triterpene compound with a significant inhibitory effect on inflammation models. anti-inflammatory agent 13 has the potential to be used in studies of DAMP or PAMP-induced inflammation.

Anti-inflammatory agent 12 is a pentacyclic triterpene compound that showed a significant bias in LPS-induced inflammatory responses (IC50: 2.22 μM). anti-inflammatory agent 12 has potential for use in inflammatory disease research.

Anti-inflammatory agent 6 exhibits anti-inflammatory potential by blocking the phosphorylation of Iκb kinase α β (IKKα β), IκBα and nuclear factor kB p65 (NF-κb p65), which are key controllers of inflammation.

Anti-inflammatory agent 18 inhibits NO activity (IC50: 15.94 μM) and has an inhibitory effect on the late inflammatory response induced by HMGB1 and can be used to study late inflammatory diseases such as coronavirus disease (COVID-19), sepsis, etc.

Anti-inflammatory agent 19 inhibits NO (IC50: 36.00 μM). anti-inflammatory agent 19 exhibits an inhibitory effect on HMGB1-induced late inflammatory responses. anti-inflammatory agent 19 can be used to study late inflammatory diseases such as Coronavirus disease (COVID-19), sepsis, etc.